NASDAQ · GRDX
Healthcare · Biotechnology
$4.80
Down-$0.28 (-5.73%)
Updated Oct 9, 2026, 5:06 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GRDX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
GRDX closed at $4.80 after 21 trading sessions, up 61.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $4.15 | $4.8922 | $4.15 | $4.80 | 207.57K |
| Oct 7, 2026 | $4.07 | $4.45 | $4.07 | $4.12 | 117.64K |
| Oct 6, 2026 | $4.10 | $4.30 | $3.92 | $4.17 | 105.2K |
| Oct 5, 2026 | $3.81 | $4.10 | $3.46 | $3.83 | 191.96K |
| Oct 2, 2026 | $3.40 | $3.91 | $3.40 | $3.81 | 107.28K |
| Oct 1, 2026 | $3.75 | $3.80 | $3.35 | $3.44 | 73.13K |
| Sep 30, 2026 | $3.30 | $3.88 | $3.30 | $3.682 | 120.79K |
| Sep 29, 2026 | $3.639 | $3.639 | $3.1591 | $3.26 | 52.25K |
| Sep 28, 2026 | $3.43 | $3.665 | $3.43 | $3.47 | 36.39K |
| Sep 25, 2026 | $3.82 | $3.88 | $3.37 | $3.43 | 134.38K |
| Sep 24, 2026 | $3.85 | $4.00 | $3.71 | $3.81 | 99.78K |
| Sep 23, 2026 | $3.99 | $4.12 | $3.77 | $3.86 | 30.45K |
| Sep 22, 2026 | $3.50 | $3.90 | $3.36 | $3.89 | 77.63K |
| Sep 21, 2026 | $3.01 | $3.44 | $3.01 | $3.40 | 52.92K |
| Sep 18, 2026 | $3.20 | $3.20 | $2.89 | $3.11 | 106.13K |
| Sep 17, 2026 | $2.99 | $3.15 | $2.95 | $3.02 | 80.52K |
| Sep 16, 2026 | $3.00 | $3.01 | $2.87 | $2.94 | 39K |
| Sep 15, 2026 | $2.8927 | $3.16 | $2.87 | $3.02 | 61.99K |
| Sep 14, 2026 | $2.85 | $3.04 | $2.745 | $2.97 | 179.57K |
| Sep 11, 2026 | $2.95 | $3.20 | $2.85 | $2.86 | 134.16K |
| Sep 10, 2026 | $3.01 | $3.29 | $2.94 | $2.97 | 69.37K |
The latest Smart Investors Daily articles mentioning GRDX.
Company
Market Activity
Research & News
GRDX research
Company profile and research snapshot.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 21, 2026
GridAI Technologies (NASDAQ:GRDX) reported quarterly losses of $(2.01) per share. This is a 773.91 percent decrease over losses of $(0.23) per share from the same period last year. The company reported $85.876 thousand
Benzinga · Feb 11, 2026
Benzinga · Feb 4, 2026
Yahoo · Jan 14, 2026
LOS ANGELES, CA - January 14, 2026 (NEWMEDIAWIRE) - GridAI Technologies (NASDAQ: GRDX) is aligning its platform with a structural shift in how the electric grid is operated as accelerating AI workloads, electrification, and distributed energy resourc...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GRDX.
